A review published in Current Pain and Headache Reports highlights the need for clinicians to remain vigilant when prescribing tramadol, as its concurrent use with opioids poses a risk of serotonin toxicity.
Prescriptions of tramadol for the treatment of headache and other types of pain have increased in recent years. Because it was not scheduled as a controlled substance by the Drug Enforcement Administration until 2014, the misconception may remain that tramadol is a safer option with less risk of dependence and adverse effects compared with other opioids. Health care providers continue to overprescribe opioids for headache despite the potential for abuse, headache-related disability, and rebound headache.2
In addition, many physicians are unaware of the risk of serotonin toxicity from opioid use, particularly when combined with antidepressant medications. This is primarily due the lack of relevant instruction in most medical schools and residency programs, according to co-author Hossein Ansari, MD, FAHS, an assistant professor of neuroscience and director of the headache clinic at the University of California, San Diego.
The physicians who most commonly prescribe opioids – pain specialists, primary care doctors, and emergency department physicians – typically have not had “even one minute of formal didactic lecture on clinical pharmacy during their residency training, so when would they learn about this interaction?” he said. “The answer is ‘never,’ so they keep prescribing since they simply do not have the medical knowledge about it,” he told Clinical Pain Advisor.
This knowledge gap can have life-threatening consequences, including the risk of serotonin toxicity, which can lead to potentially fatal serotonin syndrome (SS).
Patients either starting a serotonin-based treatment, or stepping up their dosage may develop SS triggered by overstimulation of postsynaptic serotonin receptors. Symptoms associated with SS vary widely and a lack of awareness of its features can lead to frequent under-diagnosis or misdiagnosis. The current review of relevant research found that the majority of SS cases occurred with tramadol use vs other opioid analgesics used concomitantly with a serotonergic drug.
Prevention of SS is key, and although various sets of diagnostic criteria have been developed, they may primarily identify patients with advanced serotonin toxicity. Physicians should be aware that any patient taking a serotonergic opioid, particularly in combination with another serotonergic drug, is at risk of toxicity. A detailed examination of a patient’s active medication list is critically important, and the authors propose that early detection of serotonin excess may be facilitated by viewing it along a spectrum of the following 3 stages, which may overlap in some cases.
- Mental status: anxiety, fidgetiness, restlessness
- Neuromuscular finding: hyperreflexia
- Autonomic feature: tachycardia, BP elevation from baseline
- Mental status: confusion, disorientation, agitation
- Neuromuscular finding: tremor, myoclonus
- Autonomic feature: diarrhea, vomiting, diaphoresis
- Mental status: delirium, decreased level of consciousness from stupor to coma
- Neuromuscular finding: increased tone (rigidity), clonus, positive Babinski (bilateral)
- Autonomic feature: hyperthermia, shivering, mydriasis, cardiac arrhythmias
Dr Ansari recommends that physicians avoid prescribing an opioid for a primary complaint of headache. “If you feel that a patient needs something strong for headache, simply refer the patient to a headache specialist – not to a neurologist,” most of which are not actually headache doctors, he advised. “With the current pattern of patient care, we will see more patients with serotonin toxicity, for sure,” he said.
Summary and Clinical Applicability
Physicians should be aware that any patient taking a serotonergic medication should be monitored for serotonin toxicity, and the spectrum proposed in the current review may help with detection. Early diagnosis is key to preventing progression to the life-threatening condition known as serotonin syndrome.
Limitations and Disclosures
No limitations noted. Hossein Ansari declared that he is on the Speaker’s Bureau for Teva Pharmaceutical and Avanir Pharmaceutical.
- Ansari H, Kouti L. Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment. Curr Pain Headache Rep. 2016; 20(8):50.
- Casucci G, Cevoli S. Controversies in migraine treatment: opioids should be avoided. Neurol Sci. 2013; 34 Suppl 1:S125-8.
This article originally appeared on Clinical Pain Advisor